CWChurat Weeraphan

Churat Weeraphan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Churat Weeraphan has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antibacterial Potential of Limosilactobacillus fermentum YTPP05 Against Methicillin-Resistant Staphylococcus aureus

    by Pimnipa Pornjirawittayakul, Peerapat Krittanan, Kittipot Sirichaiwetchakoon, Surachat Buddhisa, Nattaphol Prakobkaew, Ismini Nakouti, Glyn Hobbs, Churat Weeraphan, Htun Htun Win, Benjawan Dunkhunthod, et al.

    Lactic Acid Bacteria (LAB)-derived antimicrobial compounds are recognized as a promising source of novel antimicrobial agents, particularly for the treatment of Methicillin-Resistant Staphylococcus aureus (MRSA), where the mode of action and associated cellular effects remain largely unexplored. This study aims to evaluate antibacterial activity of Limosilactobacillus fermentum YTPP05 isolated from pickled radish against MRSA. Upon the initial antibacterial evaluations, it was found that strain YTPP05 inhibited the growth of MRSA isolates. Multiplex PCR identified multiple resistance genes in our MRSA strains, including mecA, blaZ, and aacA genes, aligning with antibacterial susceptibility profiles determined by the disc diffusion assay. An agar overlay assay showed that YTPP05 possessed antibacterial potential, with the largest inhibition zone diameters of 40.83 ± 8.43 mm, while the inhibition zones of the Cell Free Supernatant (CFS) of YTPP05 by an agar well diffusion were 27.16 ± 2.93 mm against the MRSA isolates. The minimum inhibitory concentration and minimum bactericidal concentration of YTPP05-derived CFS were 125 mg/mL. Scanning Electron Microscopy (SEM) demonstrated YTPP05 extracts caused cell membrane disruption, bubble-like protrusion, and cell lysis. Collectively, this study highlights the anti-MRSA potential of YTPP05 as an alternative antimicrobial agent for combating MRSA infections.

  • Open Access

    Phosphorylated filamin-A at serine 1459 from plasma-derived small extracellular vesicles as a promising biomarker for high-risk adenoma and colorectal cancer

    by Chris Verathamjamras, Juthamard Chantaraamporn, Juthaporn Sangwallek, Ladawan Khowawisetsut, Sasivimon Pramual, Phichamon Phetchahwang, Khajeelak Chiablaem, Daranee Chokchaichamnankit, Kanitta Srinoun, Natta Tansila, et al.

    Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection can reduce CRC mortality by more than 90%. Circulating small extracellular vesicles (sEVs) are emerging as promising biomarkers for CRC, but their role in detecting precancerous lesions remains unclear. Herein, parallel proteomic and phosphoproteomic analyses of plasma-derived sEVs were performed in healthy subjects with negative colonoscopy, patients with high-risk adenoma (HRA) and patients with CRC. A total of 139 phosphorylation sites on 52 proteins were identified, among which 16 phosphorylation sites on 12 sEV proteins showed significant changes (≥ 2-fold) with 90% confidence in site localization. Web-based validation demonstrated that the phosphorylation level of sEV-derived filamin-A at serine 1459 (pFLNASer1459) correlated with the Clinical Proteomic Tumor Analysis Consortium colon cancer dataset. Immunoblot analysis confirmed that sEV-derived pFLNASer1459 was significantly reduced in CRC patients compared with healthy subjects, whereas the highest levels were observed in HRA patients. Notably, sEV-derived pFLNASer1459, alone or in combination with FLNA, CD9, and TSG101, showed superior diagnostic performance in distinguishing HRA patients from CRC patients and healthy subjects. These findings suggest that plasma sEV-derived pFLNASer1459 is a promising biomarker for colorectal neoplasm detection.


  • Proteomics Analysis of C-Serum and Rubber Particles from Hevea brasiliensis (Clone RRIT 251)

    by Charinrat Saechan, Natakorn Nokchan, Suttida Saewong, Supinya Thanapongpichat, Kanitta Srinoun, Natta Tansila, Worrawit Wanichsuwan, Phanthipha Runsaeng, Juthamard Chantaraamporn, Daranee Chokchaichamnankit, et al.


  • Open Access

    Characterization and microRNA quantification of plasma-derived extracellular vesicles in patients with Plasmodium knowlesi infection

    by Thunchanok Khammanee, Natakorn Nokchan, Piyatida Molika, Hansuk Buncherd, Kanitta Srinoun, Natta Tansila, Charinrat Saechan, Rachanida Praparatana, Nongyao Sawangjaroen, Suwannee Jitueakul, et al.

    MicroRNAs (miRNAs), derived from extracellular vesicles (EVs) are circulating intercellular communicators which influence pathogenesis and could be used as potential diagnostic markers. In this study, plasma-derived EVs from Plasmodium knowlesi-infected patients (n = 13) and healthy individuals (n = 10) were isolated using size exclusion chromatography and ultracentrifugation. The presence of EVs was confirmed by transmission electron microscopy and Western immunoblotting, and quantified by nanoparticle tracking analysis. The EVs isolated from patients exhibited a larger size, accompanied by an elevated concentration of EVs. The relative expression levels of 8 human miRNAs were quantified using reverse transcriptase quantitative polymerase chain reaction. Compared to uninfected groups, hsa-miR-223-5p (P-value = 0.0002) and hsa-miR-486-5p (P-value = 0.025) were upregulated in P. knowlesi-infected patients. Bioinformatic analysis revealed that these miRNAs are predicted to target both human host and parasite genes, and they were found to be enriched in various malaria-related pathways. The areas under the receiver operating characteristic curve of hsa-miR-223-5p and hsa-miR-486-5p were 0.9154 and 0.8231, respectively, suggesting the potential of EV-miRNAs as diagnostic markers. Results revealed that EV-miRNAs may play a significant role in the progression of P. knowlesi infection. Further investigations should explore their potential impact on gene expression regulation as diagnostic biomarkers or targets for therapeutic interventions.


  • Open Access

    Proteomic analysis reveals a potential anticancer mechanism for a novel effervescent curcumin-ascorbic acid-polysaccharide-β-cyclodextrin inclusion complex towards colorectal cancer cells through modulation of ribosome biogenesis

    by Atthapan Morchang, Keerakarn Somsuan, Artitaya Rongjumnong, Churat Weeraphan, Sasivimon Pramual, Theetat Ruangjaroon, Daranee Chokchaichamnankit, Wuttichai Jaidee, Phateep Hankittichai, Chanatip Pramvichai, et al.


  • Diagonal Chromatography for the Isolation of O -Linked β-N-acetyl-D-Glucosaminylated ( O -GlcNAcylated) Peptides in HeLa Cell Extracts

    by Pongsakorn Thawornpan, Churat Weeraphan, Supinya Thanapongpichat, Charinrat Saechan, Worrawit Wanichsuwan, Kanitta Srinoun, Natta Tansila, Chris Verathamjamras, Voraratt Champattanachai, Daranee Chokchaichamnankit, et al.

  • Open Access

    Translational Proteomic Approach for Cholangiocarcinoma Biomarker Discovery, Validation, and Multiplex Assay Development: A Pilot Study

    by Kamolwan Watcharatanyatip, Somchai Chutipongtanate, Daranee Chokchaichamnankit, Churat Weeraphan, Kanokwan Mingkwan, Virat Luevisadpibul, David S. Newburg, Ardythe L. Morrow, Jisnuson Svasti, Chantragan Srisomsap

    Cholangiocarcinoma (CCA) is a highly lethal disease because most patients are asymptomatic until they progress to advanced stages. Current CCA diagnosis relies on clinical imaging tests and tissue biopsy, while specific CCA biomarkers are still lacking. This study employed a translational proteomic approach for the discovery, validation, and development of a multiplex CCA biomarker assay. In the discovery phase, label-free proteomic quantitation was performed on nine pooled plasma specimens derived from nine CCA patients, nine disease controls (DC), and nine normal individuals. Seven proteins (S100A9, AACT, AFM, and TAOK3 from proteomic analysis, and NGAL, PSMA3, and AMBP from previous literature) were selected as the biomarker candidates. In the validation phase, enzyme-linked immunosorbent assays (ELISAs) were applied to measure the plasma levels of the seven candidate proteins from 63 participants: 26 CCA patients, 17 DC, and 20 normal individuals. Four proteins, S100A9, AACT, NGAL, and PSMA3, were significantly increased in the CCA group. To generate the multiplex biomarker assays, nine machine learning models were trained on the plasma dynamics of all seven candidates (All-7 panel) or the four significant markers (Sig-4 panel) from 45 of the 63 participants (70%). The best-performing models were tested on the unseen values from the remaining 18 (30%) of the 63 participants. Very strong predictive performances for CCA diagnosis were obtained from the All-7 panel using a support vector machine with linear classification (AUC = 0.96; 95% CI 0.88–1.00) and the Sig-4 panel using partial least square analysis (AUC = 0.94; 95% CI 0.82–1.00). This study supports the use of the composite plasma biomarkers measured by clinically compatible ELISAs coupled with machine learning models to identify individuals at risk of CCA. The All-7 and Sig-4 assays for CCA diagnosis should be further validated in an independent prospective blinded clinical study.